In the first of this two-part article, I highlighted the current, cautious biosimilar climate in one IDN and some of the challenges hindering uptake. But I was pleasantly surprised by the confidence Michael Jacobs, senior director of health and wellness at Walmart, had about the positive impact the retail pharmacy model could have on biosimilars in the upcoming years.
A few months ago, Biosimilar Development published an interview with Dave Picard, VP of biosimilars and injectables for AmerisourceBergen, who shared his predictions on how biosimilars will fit into hospital distribution models. Based on the popularity of that article, we decided to reach out to another leading U.S. drug wholesaler for their perspective on the topic. In this Q&A, Chadi Nabhan, M.D., VP and chief medical officer of Specialty Solutions at Cardinal Health, discusses biosimilar uptake at the hospital level — and how biosimilar companies should be planning their distribution strategies.
After hearing presentations by two experts working in an integrated delivery network (IDN) and a retail pharmacy setting, it’s clear each has a decidedly different stance on biosimilars: one is cautious, the other confident. In the first of this two-part article, I address the current, cautious biosimilar climate in one IDN and some of the challenges hindering uptake.
During my visit to Thailand, I was privy, not only to the particularly innovative research goals being pursued, but also to a number of challenges the country has recognized and hopes to address within the next few years to encourage a stronger, more diverse industry.
A few weeks ago, I was invited by the Thailand Board of Investment to attend a media trip to learn about the country’s budding life sciences industry. Entering Thailand, a country in which the government is pushing more investment and education in the sciences, was even more striking and meaningful to me given the current scientific climate in the U.S.
The first part of this article introduced pharmacy benefit managers (PBMs) and their business model and explored the monopolization concerns in this market. The focus now turns to state and federal actions regarding PBMs.
About a month ago, I was offered a tremendous opportunity: to attend a media trip to Thailand to learn about the country’s burgeoning life sciences industry. Like many people in the life sciences industry, I had no idea just how much has been going on within the country in terms of life sciences.
This article summarizes insights gleaned from interviews with multiple consultants, each of whom has at least 25 years’ experience in the life sciences space — and from conversations with the life science companies who hire such consultants to ensure that their systems meet the product quality attribute/specification requirements mandated by their respective regulators.
These are formative days for biosimilar developers in the U.S. courts. Last month, the biosimilar market witnessed its first legal settlement, between Mylan and Genentech for trastuzumab, and further settlements are sure to follow. On April 26, the Supreme Court began hearing the case between Amgen and Sandoz regarding the infamous “patent dance.” The Court’s ruling (expected in July) will have significant ramifications on how quickly new biosimilars reach the market.
It’s unlikely biosimilar applications containing only analytical and preclinical data will meet the FDA’s demands for totality of the evidence within the next few years. However, a changing political climate urging quicker development and lower drug prices has only intensified the discussion within the biosimilar industry about developmental efficiency.